Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With BRAF-Altered, Recurrent or Progressive Low-Grade Glioma
Protocol ID
DAY101-001 (FIREFLY)
Disease (Sub Disease)
Low-grade Glioma
Diagnosis Stage
Relapse/refractory
Location
NSW, WA
Sponsor
Day One Biopharmaceuticals, Inc.
Collaborators
Pacific Pediatric Neuro-Oncology Consortium
Trial Status
Open
Sites
Perth Children's Hospital
Sydney Children's Hospital
Children's Hospital at Westmead
Study Type
Treatment
Phase
Phase 2
Age Eligibility
6 Months to 25 Years
International registry ID's
NCT04775485
Back to Registry
Study Title A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With BRAF-Altered Recurrent or Progressive Low-Grade Glioma
Protocol ID DAY101-001 (FIREFLY)
Disease (Sub Disease) Low-grade Glioma
Diagnosis Stage Relapse/refractory
Location NSW / WA
Sponsor Day One Biopharmaceuticals, Inc.
Collaborators Pacific Pediatric Neuro-Oncology Consortium
Links https://clinicaltrials.gov/ct2/show/NCT04775485
Trial Status Open
Trial Open Date 17/03/2021
Sites Perth Children's Hospital / Sydney Children's Hospital / Children's Hospital at Westmead
Study Type Treatment
Phase Phase 2
Age Eligibility 6 Months to 25 Years
International registry ID's NCT04775485